- Home
- RIGL vs BWMN Comparison
RIGL vs BWMN Comparison
Compare RIGL & BWMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RIGL | BWMN |
|---|---|---|
| Founded | 1996 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Military/Government/Technical |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 628.4M | 620.2M |
| IPO Year | 2000 | 2021 |
Fundamental Metrics
Financial Performance| Metric | RIGL | BWMN |
|---|---|---|
| Price | $29.44 | $30.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $45.67 | $45.50 |
| AVG Volume (30 Days) | ★ 261.8K | 151.8K |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1867.68 | 329.41 |
| EPS | ★ 19.48 | 0.73 |
| Revenue | $294,282,000.00 | ★ $490,017,000.00 |
| Revenue This Year | N/A | $16.80 |
| Revenue Next Year | $12.75 | $11.77 |
| P/E Ratio | ★ $1.57 | $42.56 |
| Revenue Growth | ★ 64.15 | 14.88 |
| 52 Week Low | $16.05 | $20.93 |
| 52 Week High | $52.24 | $45.83 |
Technical Indicators
Market Signals| Indicator | RIGL | BWMN |
|---|---|---|
| Relative Strength Index (RSI) | 53.67 | 55.28 |
| Support Level | $28.08 | $30.48 |
| Resistance Level | $30.59 | $36.83 |
| Average True Range (ATR) | 1.10 | 1.32 |
| MACD | 0.74 | 0.46 |
| Stochastic Oscillator | 77.44 | 80.00 |
Price Performance
Historical ComparisonAbout RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About BWMN Bowman Consulting Group Ltd.
Bowman Consulting Group Ltd is a professional services firm delivering engineering solutions to customers who own, develop, and maintain the built environment. It provides planning, engineering, construction management, commissioning, environmental consulting, geospatial, survey, land procurement, and other technical services to customers operating in a diverse set of end markets. Its services include Civil & Site Engineering, Transportation Engineering, MEP Engineering, Commissioning & Energy Efficiency, Energy Services, Water/Wastewater, Fire Protection, Construction Management, Survey/Geospatial, Environmental Consulting, Structural Engineering, Land Procurement & Right-of-Way, Landscape and Architecture/Planning.